Seeking Alpha

Amarin (AMRN -0.6%) lags the general market after being being given a less than enthusiastic...

Amarin (AMRN -0.6%) lags the general market after being being given a less than enthusiastic initiation by analysts at Chardan Capital Markets with a Hold rating and a price target of $8.50 a share. The firm says that the chance for a strategic deal over the near-term is low, and Vascepa faces risks of a tepid debut.
Comments (17)
  • ralphey
    , contributor
    Comments (323) | Send Message
     
    Hmm as a practicing Doc its on fire in my practice 20 Rx s written this week !!
    20 Mar 2013, 01:12 PM Reply Like
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
     
    Ralph - Did you get the insurance rejection issue for Vascepa get fixed in your practice?
    20 Mar 2013, 02:10 PM Reply Like
  • Jaskamaric
    , contributor
    Comments (45) | Send Message
     
    Hi Ralphey, if you don't mind me asking, what city do you work in?
    I live in Houston and I have visited several pharmacies just to chat and most of the staff at these places hasn't even heard of Vascepa.
    20 Mar 2013, 04:43 PM Reply Like
  • ralphey
    , contributor
    Comments (323) | Send Message
     
    Yes it is much better at this point. I would say about 80% of the rx's are going through. No call backs from patients so appears to be well tolerated. Will be getting results of lipid panels on most of these in about 6 weeks and will see what has happened to trig and LDL. Most of these scripts are replacing lovaza - next are new rx's.

     

    It is now Tier two on many plans some tier 3. Amarin dropped off copay cards for the rest. I am surprised at how fast it has become accepted by insurance companies - if they see no value in a new med thy often will not approve it or you have to get pre auths etc - in several weeks almost all of those barriers dropped with vascepa - that is unusual and indicates to me that the insurance formularies see a distinct advantage with this medication in preserving health and preventing morbidity and mortality - otherwise there is no way they would pay for it
    22 Mar 2013, 01:16 PM Reply Like
  • ralphey
    , contributor
    Comments (323) | Send Message
     
    I am in the Northeast - rural - - upstate NY - your rep was in last week he would know me
    22 Mar 2013, 01:17 PM Reply Like
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
     
    Thanks for the color Ralph
    26 Mar 2013, 09:14 PM Reply Like
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
     
    Ralph - Are you doing the lipid panels on the ex Lovaza patients to see if Vascepa is differentiated or just standard periodic lipid panels for these patients?

     

    What is the profile of patients that would be receiving omega 3 in the form of Vascepa for the first time?

     

    Thanks much.
    26 Mar 2013, 09:21 PM Reply Like
  • William LeGro
    , contributor
    Comments (108) | Send Message
     
    I want Amarin's next drug to be a combo antidepressant, stimulant and tranquilizer. A "What? Me worry?" drug. Now that would be a blockbuster, at least among Amarin investors.
    20 Mar 2013, 01:51 PM Reply Like
  • skirkbond
    , contributor
    Comments (13) | Send Message
     
    I just don't see how they can lose. Lovaza is a money maker, yet Vascepa is more effective with less drawbacks. Why would anyone prescribe Lovaza when Vascepa is so much better? Vascepa should eventually eliminate Lovaza from the market. Once Anchor is approved, it's going to take off. I believe this enough to hold 5,500 shares.
    20 Mar 2013, 02:33 PM Reply Like
  • Jaskamaric
    , contributor
    Comments (45) | Send Message
     
    Yes, Vescepa is a better drug than Lovaza...but ultimately if the physician does not have that information it will not matter. AMRN needs to market this drug better which is hard to do without Big Pharma. Our sales force will have to do an incredible job. If Q3 sales scripts are good I will add to my position. Still long but now that the drug is on the market the only thing that will talk are #s!

     

    This damn NCE delay isn't exactly helping us either.
    20 Mar 2013, 04:41 PM Reply Like
  • yourmama6799
    , contributor
    Comments (487) | Send Message
     
    Jaskamaric,
    There is no way in hell that we will get big scripts only because our sales force is so miniscule overall. Do you realize that Reliant had 600 reps at the start of their launch and no fish oil competition? I read that GSK has 1200 reps focusing on Lovaza.

     

    I see a partnership in our future, no BO, NCE is an issue, but I do not believe the company is worth more than 15.00 a share or so. I hear people conveying $30.00 a share, that would put us at a market cap of five billion, come on...
    20 Mar 2013, 09:20 PM Reply Like
  • Jaskamaric
    , contributor
    Comments (45) | Send Message
     
    Yeah our sales force is too small. I would be happy with 15 at this point...
    21 Mar 2013, 11:25 AM Reply Like
  • timmr21
    , contributor
    Comments (27) | Send Message
     
    Funny AMRN was once a 180 a share stock.and has spent months around 30 something tells me that this one is being news-ed down for some reason.

     

    I doubled down shy of 8.50 dont see how this one can lose long term at that number
    21 Mar 2013, 02:21 AM Reply Like
  • 5967241
    , contributor
    Comments (88) | Send Message
     
    There is a nice SA article on the accuracy of Chardan Capital Markets. Check this out ---> http://tinyurl.com/3t9...
    21 Mar 2013, 06:30 AM Reply Like
  • drrc1949
    , contributor
    Comments (8) | Send Message
     
    The array of inept sources of information relied upon by these analysts amazes me. Quote: "A survey showed curbed enthusiasm for Vascepa and an undifferentiated clinical profile compared to three other therapies" - Unquote. Where did you find this survey.....on Family Feud? I'm retired but looking for part-time work.....can HR from Chardan Capital Markets please contact me? I think I have what it takes to make it as one of your crack analysts!

     

    If your "analyst" had spent 15 minutes researching Vascepa, he/she could not possibly have used the above quote as it is blatantly misleading at best. I will not attempt to make the case for Amarin's success or failure. BUT I will state that if this is the best you've got, then Chardan Capital Markets should start developing a New Business Model. You're not gonna make it at this!!
    21 Mar 2013, 07:15 AM Reply Like
  • listech
    , contributor
    Comments (19) | Send Message
     
    Amen, drrc1949!
    AMRN is going to be a winner but they need to get out there and sell the story and who cares what the analysts say. They're never right anyway!
    21 Mar 2013, 11:42 AM Reply Like
  • ralphey
    , contributor
    Comments (323) | Send Message
     
    THe VAscepa story reminds me of Crestor. When Crestor initially came out it was clear that it was the best statin - yet it floundered for years after getting initial bad press - however, since it clearly was the best drug in class it has survived and is now a winner - the same will be true of vascepa unless it is replaced by a superior med
    22 Mar 2013, 01:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|